MiRNA-Mediated Regulation of S100B: A Review.

IF 2 Q3 CLINICAL NEUROLOGY
NeuroSci Pub Date : 2025-08-08 DOI:10.3390/neurosci6030075
Animesh Dali, Suhana Basnyat, Rachel Delancey, Nipun Chopra
{"title":"MiRNA-Mediated Regulation of S100B: A Review.","authors":"Animesh Dali, Suhana Basnyat, Rachel Delancey, Nipun Chopra","doi":"10.3390/neurosci6030075","DOIUrl":null,"url":null,"abstract":"<p><p>S100β is a significant signaling molecule and biomarker that is primarily expressed in the brain. At low physiological concentrations, S100β induces astrocyte maturation, microglial migration, and neural proliferation. However, high concentrations activate inflammatory and pro-apoptotic pathways. Due to this dual role, increased research is being invested into the role of S100β in neuronal homeostasis and inflammation. In fact, increased S100β expression is seen in many neuropathologies including Alzheimer's disease, Parkinson's disease, cerebral ischemia, and traumatic brain injury. High S100β is generally associated with worsened disease outcome. Here, we provide an overview of the structure and role of S100β in various pathways, particularly in the context of neurological disorders. Modulation of S100β levels also holds promise as a therapeutic strategy. Micro-RNAs (miRNA) post-transcriptionally regulate gene expression and provide a novel approach reduce excess S100β protein. However, much of this research is still in its infancy. We outline current studies identifying miRNA in human and animal models of various neurological disorders. S100β itself has several predicted miRNA interactions although most have not yet been directly validated. Together, we compile the literature identifying S100β and miRNAs to guide future research in this field. We also comment on the feasibility and future uses of miRNA for pharmaceutical regulation of S100β, particularly for neurological treatments.</p>","PeriodicalId":74294,"journal":{"name":"NeuroSci","volume":"6 3","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12371975/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NeuroSci","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/neurosci6030075","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

S100β is a significant signaling molecule and biomarker that is primarily expressed in the brain. At low physiological concentrations, S100β induces astrocyte maturation, microglial migration, and neural proliferation. However, high concentrations activate inflammatory and pro-apoptotic pathways. Due to this dual role, increased research is being invested into the role of S100β in neuronal homeostasis and inflammation. In fact, increased S100β expression is seen in many neuropathologies including Alzheimer's disease, Parkinson's disease, cerebral ischemia, and traumatic brain injury. High S100β is generally associated with worsened disease outcome. Here, we provide an overview of the structure and role of S100β in various pathways, particularly in the context of neurological disorders. Modulation of S100β levels also holds promise as a therapeutic strategy. Micro-RNAs (miRNA) post-transcriptionally regulate gene expression and provide a novel approach reduce excess S100β protein. However, much of this research is still in its infancy. We outline current studies identifying miRNA in human and animal models of various neurological disorders. S100β itself has several predicted miRNA interactions although most have not yet been directly validated. Together, we compile the literature identifying S100β and miRNAs to guide future research in this field. We also comment on the feasibility and future uses of miRNA for pharmaceutical regulation of S100β, particularly for neurological treatments.

Abstract Image

Abstract Image

Abstract Image

mirna介导的S100B调控研究进展
S100β是一种重要的信号分子和生物标志物,主要在大脑中表达。在低生理浓度下,S100β诱导星形胶质细胞成熟、小胶质细胞迁移和神经细胞增殖。然而,高浓度激活炎症和促凋亡途径。由于这种双重作用,越来越多的研究投入到S100β在神经元稳态和炎症中的作用。事实上,S100β表达增加在许多神经病变中都可见,包括阿尔茨海默病、帕金森病、脑缺血和创伤性脑损伤。高S100β通常与疾病预后恶化相关。在这里,我们概述了S100β在各种途径中的结构和作用,特别是在神经系统疾病的背景下。调节S100β水平也有望成为一种治疗策略。微rna (miRNA)转录后调控基因表达,提供了一种减少过量S100β蛋白的新方法。然而,这方面的许多研究仍处于起步阶段。我们概述了目前在各种神经系统疾病的人类和动物模型中鉴定miRNA的研究。S100β本身有几种预测的miRNA相互作用,尽管大多数尚未直接验证。我们共同整理了鉴定S100β和mirna的文献,以指导该领域的未来研究。我们还评论了miRNA在S100β药物调控方面的可行性和未来应用,特别是在神经治疗方面。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
11 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信